MASH

Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH).

liver

Biotech

D&D sees fibrosis improvements, MASH resolution on GLP-1 drug

D&D linked its GLP-1/glucagon drug to liver health improvements, keeping the Korean biotech in the hunt for a market already served by Novo's Wegovy.

Nick Paul Taylor May 27, 2026 10:30am

blood test vial

New Hepta blood test could predict GLP-1 response

May 9, 2026 3:08am

Liver

Madrigal boosts MASH pipeline with $1B biobucks Arrowhead deal

May 5, 2026 10:40am

liver

Madrigal pens $4.4B deal for siRNA drugs in fresh Rezdiffra play

Feb 11, 2026 7:40am

target reach ladder climb meet win beat competition

OrsoBio hits target in midstage study for metabolic conditions

Feb 10, 2026 8:00am

liver

Madrigal pays Pfizer $50M for MASH drug with combo potential

Jan 9, 2026 10:50am